TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01382316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Alcoholics Anonymous Easier (MAAEZ)
Description: 6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Group format, six weekly education sessions about alcohol and drugs
Study: NCT02961062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAF312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00807391

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TBCA, TBNA
Description: One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
Study: NCT03013296

Intervention type: OTHER
Group type: OTHER
Intervention: GIP-A
Description: GIP-A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 receptor antagonist Exendin[9-39]
Description: Exendin\[9-39\]

Intervention type: OTHER
Group type: OTHER
Intervention: GIP-A + Exendin[9-39]
Description: GIP-A + Exendin\[9-39\]
Study: NCT03349905

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fresh transfer
Description: Women randomized in the non experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~* All of their embryo kept in prolonged culture~* A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~* Supernumerary blastocysts cryopreserved

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred-frozen embryo transfer
Description: Women randomized in the experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~* All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~* A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation
Study: NCT02604173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo pill and sham inhaler
Study: NCT04549376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.4% NI
Description: Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.5% NI
Description: Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.6% NI
Description: Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.5% NS
Description: Povidone iodine (PVP-I) nasal spray at concentration of 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.6% NS
Description: Povidone iodine (PVP-I) nasal spray at concentration of 0.6%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: DW-NI
Description: Nasal irrigation will be provided by Distilled water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: DW-NS
Description: Nasal spray will be provided by Distilled water
Study: NCT02555124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 5 mg
Description: Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 20 mg
Description: Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 40 mg
Description: Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
Study: NCT02332564

Intervention type: OTHER
Intervention: Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
Description: Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index

Intervention type: OTHER
Intervention: Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
Description: Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
Study: NCT01810705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
Study: NCT00574249

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol/Betamethasone Ointment
Description: Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (vehicle ointment)
Description: Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
Study: NCT03070405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Single oral dose on the first day of each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Single oral dose on the first day of each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminosalicylic acid Ca granule 5.28 g
Description: Twice daily oral administration from the first day of each period to the seventh dose
Study: NCT04944303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equal doseage of normal saline was injected to reverse the NMB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Equal doseage of normal saline was injected to reverse the NMB.
Study: NCT02175381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
Study: NCT02322450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00955981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA594
Description: Uricosuric agent for the treatment of gout

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA594
Description: Uricosuric agent for the treatment of gout

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA594
Description: Uricosuric agent for the treatment of gout

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04559035

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal lavage
Description: Twice daily nasal lavage.

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal lavage
Description: Twice daily nasal lavage.
Study: NCT00810017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
Study: NCT03042754

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: XpertMTB/RIF
Study: NCT00664456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy
Description: 3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
Study: NCT01288092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Study: NCT02110030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation
Description: The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Currents
Description: The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and V deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain).
Study: NCT03541109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)
Study: NCT03526198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Force plate
Description: Device: force plate An equipment model with the approach of providing the evaluated person with the movement that is closest to the biomechanical and functional reality of the ankle and foot joint and which could equalize the possible changes of the center of mass would contribute to the clinical evaluation and would provide a more efficient therapeutic reasoning rehabilitation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Force plate
Description: Device: force plate An equipment model with the approach of providing the evaluated person with the movement that is closest to the biomechanical and functional reality of the ankle and foot joint and which could equalize the possible changes of the center of mass would contribute to the clinical evaluation and would provide a more efficient therapeutic reasoning rehabilitation.
Study: NCT00231283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)
Description: CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
Study: NCT03057223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed patient-specific titanium plates
Description: 3D-printed patient-specific titanium plates will be used in patients.
Study: NCT00394134

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview
Description: Interviews to describe the sun exposure and sun protection practices of patients and their children.
Study: NCT01094782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Subjects receive 6 acupuncture treatments for neck or back pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Subjects receive 6 acupuncture treatments for neck or back pain.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Subjects receive 6 sham acupuncture treatments for neck or back pain.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Subjects receive 6 sham acupuncture treatments for neck or back pain.
Study: NCT02253121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sliding scale insulin
Description: Sliding scale insulin with short acting insulin based on current glucose levels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sliding scale insulin
Description: Sliding scale insulin with short acting insulin based on current glucose levels
Study: NCT01902355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified Seldinger technique
Description: modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger technique
Description: The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
Study: NCT03776071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzastaurin Hydrochloride
Description: mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: mg/m\^2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: mg/m\^2

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Gy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Gy
Study: NCT02904551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral prophylaxis
Description: Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
Study: NCT03242642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Description: mitral valve replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Description: mitral valve replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Description: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Description: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement
Study: NCT02960555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03781583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHMD version 1
Description: First version of the SmartHMD device, which used custom software running on commercially available ODG R7 smart glasses and accompanying earbuds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHMD version 2
Description: Second version of the SmartHMD device, which uses RGB-D smart glasses, custom software running on a laptop, and bone-conducting earphones.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHMD version 3
Description: Third iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and custom software.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHMD version 4
Description: Fourth iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and a specific version of custom software.
Study: NCT04424511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
Study: NCT01866267

Intervention type: DRUG
Group type: OTHER
Intervention: Maraviroc
Description: HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
Study: NCT00435019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: s.c. injection, once or twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: s.c. injection, once or twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: s.c. injection, at main meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: s.c. injection, at main meals.
Study: NCT00311103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific clinical care program
Description: The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
Study: NCT03909854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mode of mechanical ventilation
Description: Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mode of mechanical ventilation
Description: Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.
Study: NCT03679169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreatosplenectomy
Description: standard or radical anterograde modularpancreatosplenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreatosplenectomy
Description: standard or radical anterograde modularpancreatosplenectomy